1 / 7

Blockbuster Drugs at Risk:Navigating Pharma's Patent Cliff .

Blockbuster drugs face Loss of Exclusivity (LOE), triggering generic competition and reshaping pharma strategies for growth and market access.

Healthark
Download Presentation

Blockbuster Drugs at Risk:Navigating Pharma's Patent Cliff .

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Blockbuster Drugs at Risk The Coming Wave of Patent Expirations

  2. Blockbuster Drugs at Risk: The Coming Wave of Patent Expirations Keytruda Lenvima Lynparza 2028 2025 2027 Januvia/ Janumet Gardasil 9 2028 2026

  3. Blockbuster Drugs at Risk: The Coming Wave of Patent Expirations Prevnar Ibrance 2026 2027 Eliquis Xtandi 2028 2027

  4. Blockbuster Drugs at Risk: The Coming Wave of Patent Expirations Yervoy Eliquis Opdivo 2025 2026 2028

  5. Blockbuster Drugs at Risk: The Coming Wave of Patent Expirations Farxiga Soliris 2025 2025

  6. Blockbuster Drugs at Risk: The Coming Wave of Patent Expirations Entresto Xolair Jakafi 2025 2025 2026 Cosentyx Tafinlar Ilaris 2030 2023 2026

  7. Blockbuster Drugs at Risk: The Coming Wave of Patent Expirations Eylea 2024

More Related